周剂量多西他赛联合顺铂、5-FU治疗晚期食管癌的临床观察

目的：观察周剂量多西他赛联合顺铂、5-FU治疗晚期食管癌的临床疗效及不良反应。方法：47例晚期食管癌患者,应用多西他赛30mg/m2静脉滴注第1、8、15天,顺铂20mg/m2静脉滴注第1-5天,5-FU500mg/m2静脉滴注第1-5天,每28天重复。治疗2个周期评价疗效,每周期评价毒性。结果：47例患者均可评价疗效。获CR 3例,PR 21例,总有效率（CR＋PR）为51.06%。所有患者中位疾病进展时间为149天,中位生存时间274天。主要不良反应为骨髓抑制,出现Ⅲ/Ⅳ度中性粒细胞减少13例（27.7%）,Ⅲ度血小板减少3例（6.4%）,Ⅲ度贫血5例（10.6%）,无治疗相关性死亡。结论：周剂量多西他赛联合顺铂、5-FU治疗晚期食管癌疗效较好,毒性可以耐受,值得临床进一步研究。

Weekly docetaxel combined with cisplatin and 5-Fu in patients with advanced esophageal carcinoma

Objective：To evaluate the clinical efficacy and toxicity of weekly docetaxel combined with cisplatin and 5-FU in patients with advanced esophageal carcinoma.Methods： Total of 47 patients with advanced esophageal carcinoma received docetaxel 30mg/m2 iv d1,8,15,cisplatin 20mg/m2 iv d1-5,5-FU 500mg/m2 iv d1-5.Treatments were repeated every 28 days.The clinical responses were assessed after two cycles.Toxicity was assessed every cycle.Results： All of the 47 patients were assessable for response,3 case of complete response and 21 cases of partial response were confirmed,eith an overall response rate of 51.06%.The median time to progression（TTP） was 149 days and the median survival time（MST） was 274 days.The major toxicity was myelosuppression,neutropenia of grade III/IV occurred in 13 patients（27.7%）,thrombocytopenia of grade III in 3 patients（6.4%） and anemia of III in 5 patients（10.6%）.There was no treatment-related death.Conclusion： Weekly docetaxel combined with cisplatin and 5-FU is effective and well tolerated for patients with advanced esophageal carcinoma.